Lupus patients who take their medications at lower risk for type 2 diabetes

Issue: BCMJ, vol. 62, No. 2, March 2020, Page 69 News

An Arthritis Research Canada study has revealed that patients with lupus who take their medications as prescribed have a reduced risk of developing type 2 diabetes compared to lupus patients who do not. There is no cure for the chronic autoimmune disease that affects several parts of the body, with symptoms changing often and varying from person to person. Medications for lupus primarily focus on easing a patient’s symptoms and reducing inflammation. Hydroxychloroquine, a medicine used to treat malaria and for patients dealing with lupus flares, also has the ability to potentially reduce the risk of type 2 diabetes.

Using BC health data that include information on prescriptions, health care visits, and hospitalizations, Arthritis Research Canada research scientist Dr Mary De Vera and her team studied lupus patients over 4 years. They found that compared to those who did not take their medications as prescribed, namely hydroxychloroquine, those who did had a 39% lower risk of developing type 2 diabetes. From prior research, researchers know that an average of 43% to 75% of lupus patients do not take their medications as prescribed.

The study targeted type 2 diabetes as a known complication of lupus and is the first study to evaluate the link between nonadherence to antimalarial medication and lupus patients.

The study, “Adherence to antimalarial therapy and risk of type 2 diabetes mellitus among patients with systemic lupus erythematosus: A population‐based study,” is published in Arthritis Care and Research and is available online at https://doi.org/10.1002/acr.24147.

. Lupus patients who take their medications at lower risk for type 2 diabetes. BCMJ, Vol. 62, No. 2, March, 2020, Page(s) 69 - News.


Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply